Navigation Links
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Date:5/8/2008

sis. (See Boxed Warning.)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Patients of all ages started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL XR is not approved for use in patients under the age of 18 years. SEROQUEL XR is not approved for the treatment of depression; however, an immediate release form of quetiapine is approved for the treatment of bipolar depression. (See Boxed Warning.)

Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse events in patients treated with atypical antipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

A potentially fatal symptom complex, sometimes referred to as Neuroleptic Malignant Syndrome (NMS), has been reported in association with administration of antipsychotic drugs, including quetiapine. Rare cases of NMS have been reported with quetiapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic insta
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...he Cancer Research Alliance, an,organization compr...asking,303 million Americans to exercise their pow...fforts this Mother,s Day through Father,s Day., T..." has two key goals:,to activate Americans everywh...g together to exercise their collective power over...
(Date:5/8/2008)...tential of asenapine in the treatment of ...HINGTON, May 8 /- Schering-...hat an overview of asenapine clinical trials,from ...ual Meeting of the,American Psychiatric Associatio...ies, involving patients with bipolar I disorder an...
(Date:5/8/2008)...ire-FirstCall/ -- Siemens Healthcare and,Laborator...today announced,that they have entered a non-exclu...co-develop new clinical diagnostic tests in the ar...oncology and diabetes. Under the,agreement, initia...hat,could make the biggest impact to patient care....
(Date:5/8/2008)...wire-FirstCall/ -- VION PHARMACEUTICALS,INC. (Nas...tigator-sponsored,Phase I/II clinical trial of its...in combination with cytarabine in elderly patients...mia (AML) and high-risk,myelodysplastic syndromes ...ction of Ellen K. Ritchie, M.D. at The Weill-Corne...
Breaking Medicine Technology:World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3RxElite Filling Critical Requirement for Strategic Partners in Asia Europe and Australia 3837 1RxElite Filling Critical Requirement for Strategic Partners in Asia Europe and Australia 3837 2Cogdell Spencer Inc Announces the Closing of the Marshall Erdman and Associates Merger 13970 1Cogdell Spencer Inc Announces the Closing of the Marshall Erdman and Associates Merger 13970 2Hospital Caregivers Unveil Billboards Calling for Improved Patient Care Quality Jobs at Community Medical Centers 13967 1Kaiser Permanente Team Builds Prosthetic Hands for Charity 13964 1Kaiser Permanente Team Builds Prosthetic Hands for Charity 13964 2
(Date:5/13/2008)... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCa...oard: CSKI), a manufacturer, marketer and,distribu...oducts in China,today announced that it will cond... May 15, 2008 to discuss its first quarter 2008 fi...man, CEO and Director of China Sky One,Medical, In...
(Date:5/13/2008)...ildbearing had no such benefit if baby was bottle-...13 (HealthDay News) -- Women who breast feed for m...arthritis (RA) by half, according to a new Swedish...g children but not breast-feeding offered women no...contraceptives also failed to reduce the risk of R...
(Date:5/13/2008)...NEW YORK (May 13, 2008) -- Promising results from ...ell Medical Center physician-scientists show that ... the progression of Batten disease, or Late Infant..., genetic, degenerative neurological disorder that... to 12. , The clinical trial found that the pro...
(Date:5/13/2008)... SALT LAKE CITY, May 13 /PRNewswire/ -- Paramed S...ent of their marine-grade Mobility Offers,Versatil...chair to oil and,gas platform operators in the Gul...platforms will enable the safe and timely evacuati...atform., Paramed developed the dual-track MOV in ...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
... tortillas probably doesn't come to mind. But a Ka...with ways to add fiber to the foods we love witho.... Sajid Alavi is an assistant professor of grain ...ollege of Agriculture. His expertise is in extrusi...
...otting protein found in circulating blood, has bee...ystem neuronal cells , a process that is necessary...umatic injury. The findings by researchers at the...CSD) School of Medicine, may explain why the human...
...12 weeks pregnant with rocker boyfriend Joel Madde...fe" star, is reported to have shared the joyful ne...cluding Mischa Barton. However, she is neither co...r pregnancy to the media. Apart from her impendin...
...covered from the bottom of a two-kilometre thick i...s much warmer at some point during the last Ice Ag...e trees, plants and insects of a boreal forest est...,000 years old. Previously, the youngest evidence ...
Other Medicine News:Health News:Snack Foods Fortified With Fiber 2Health News:Fibrinogen may Inhibit Spinal Cord Regeneration 2
VG2 PLIF Allograft is comprised of two cortical planks of bone surrounding a cancellous center. The cortical planks provide strength for anterior column support. The cancellous bone provides a lattic
Williams Micro Discectomy Instruments are designed to be used in the microsurgical treatment of herniated disks.
Meyerding Laminectomy Retractors, self-retaining.
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment.
Medicine Products: